Cargando…

US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?

Finasteride competitively inhibits 5α-reductase (5-AR) isoenzymes, which blocks dihydrotestosterone (DHT) production, thereby reducing DHT. Finasteride is used in the management of benign prostatic hyperplasia (BPH) and androgenic alopecia. Amid patient reports of suicidal ideation (SI), the Post Fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Saffar, Haidar, Xu, Jennifer, O'Brien, Jonathan S., Kelly, Brian D., Murphy, Declan G., Lawrentschuk, Nathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172713/
https://www.ncbi.nlm.nih.gov/pubmed/37182121
http://dx.doi.org/10.1016/j.euros.2023.04.009
_version_ 1785039670600531968
author Al Saffar, Haidar
Xu, Jennifer
O'Brien, Jonathan S.
Kelly, Brian D.
Murphy, Declan G.
Lawrentschuk, Nathan
author_facet Al Saffar, Haidar
Xu, Jennifer
O'Brien, Jonathan S.
Kelly, Brian D.
Murphy, Declan G.
Lawrentschuk, Nathan
author_sort Al Saffar, Haidar
collection PubMed
description Finasteride competitively inhibits 5α-reductase (5-AR) isoenzymes, which blocks dihydrotestosterone (DHT) production, thereby reducing DHT. Finasteride is used in the management of benign prostatic hyperplasia (BPH) and androgenic alopecia. Amid patient reports of suicidal ideation (SI), the Post Finasteride Syndrome advocacy group has petitioned for either a stop to selling of the drug or advertisement of stronger warnings. The US Food and Drug Administration recently added SI to the adverse effects listed for finasteride. Here we provide a brief but comprehensive review of the literature on the psychological side effects of 5-AR inhibitors (5-ARIs) to provide an opinion to help in guiding treating urologists. Most of the current evidence, obtained from the literature on dermatology, suggests that 5-ARI users experience a higher rate of depressive symptoms. However, given the lack of comprehensive randomised studies, the causal link between finasteride and SI remains unclear. Urologists prescribing 5-ARIs should be aware of the recent addition of suicide and SI risk to the list of side effects. A mental health screen should be performed and appropriate resources provided to patients commencing treatment. Furthermore, a review should be arranged with the general practitioner to assess new-onset mental health or SI symptoms. PATIENT SUMMARY: We provide recommendations for urologists who prescribe finasteride for the treatment of benign prostate enlargement. Urologists should be aware of the recent addition of suicidal ideation to the list of side effects for this drug. Finasteride prescription should be continued; however, we recommend a detailed medical history to screen for prior mental health and personality disorders, with discontinuation of the medication in patients with new onset of depression or suicidal symptoms. Close liaison with the patient’s general practitioner is vital for management of depressive or suicidal symptoms.
format Online
Article
Text
id pubmed-10172713
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101727132023-05-12 US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know? Al Saffar, Haidar Xu, Jennifer O'Brien, Jonathan S. Kelly, Brian D. Murphy, Declan G. Lawrentschuk, Nathan Eur Urol Open Sci Brief Correspondence Finasteride competitively inhibits 5α-reductase (5-AR) isoenzymes, which blocks dihydrotestosterone (DHT) production, thereby reducing DHT. Finasteride is used in the management of benign prostatic hyperplasia (BPH) and androgenic alopecia. Amid patient reports of suicidal ideation (SI), the Post Finasteride Syndrome advocacy group has petitioned for either a stop to selling of the drug or advertisement of stronger warnings. The US Food and Drug Administration recently added SI to the adverse effects listed for finasteride. Here we provide a brief but comprehensive review of the literature on the psychological side effects of 5-AR inhibitors (5-ARIs) to provide an opinion to help in guiding treating urologists. Most of the current evidence, obtained from the literature on dermatology, suggests that 5-ARI users experience a higher rate of depressive symptoms. However, given the lack of comprehensive randomised studies, the causal link between finasteride and SI remains unclear. Urologists prescribing 5-ARIs should be aware of the recent addition of suicide and SI risk to the list of side effects. A mental health screen should be performed and appropriate resources provided to patients commencing treatment. Furthermore, a review should be arranged with the general practitioner to assess new-onset mental health or SI symptoms. PATIENT SUMMARY: We provide recommendations for urologists who prescribe finasteride for the treatment of benign prostate enlargement. Urologists should be aware of the recent addition of suicidal ideation to the list of side effects for this drug. Finasteride prescription should be continued; however, we recommend a detailed medical history to screen for prior mental health and personality disorders, with discontinuation of the medication in patients with new onset of depression or suicidal symptoms. Close liaison with the patient’s general practitioner is vital for management of depressive or suicidal symptoms. Elsevier 2023-04-29 /pmc/articles/PMC10172713/ /pubmed/37182121 http://dx.doi.org/10.1016/j.euros.2023.04.009 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Correspondence
Al Saffar, Haidar
Xu, Jennifer
O'Brien, Jonathan S.
Kelly, Brian D.
Murphy, Declan G.
Lawrentschuk, Nathan
US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
title US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
title_full US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
title_fullStr US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
title_full_unstemmed US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
title_short US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
title_sort us food and drug administration warning regarding finasteride and suicidal ideation: what should urologists know?
topic Brief Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172713/
https://www.ncbi.nlm.nih.gov/pubmed/37182121
http://dx.doi.org/10.1016/j.euros.2023.04.009
work_keys_str_mv AT alsaffarhaidar usfoodanddrugadministrationwarningregardingfinasterideandsuicidalideationwhatshouldurologistsknow
AT xujennifer usfoodanddrugadministrationwarningregardingfinasterideandsuicidalideationwhatshouldurologistsknow
AT obrienjonathans usfoodanddrugadministrationwarningregardingfinasterideandsuicidalideationwhatshouldurologistsknow
AT kellybriand usfoodanddrugadministrationwarningregardingfinasterideandsuicidalideationwhatshouldurologistsknow
AT murphydeclang usfoodanddrugadministrationwarningregardingfinasterideandsuicidalideationwhatshouldurologistsknow
AT lawrentschuknathan usfoodanddrugadministrationwarningregardingfinasterideandsuicidalideationwhatshouldurologistsknow